Allarity Therapeutics, Inc. (ALLR)
NASDAQ:ALLR
Top Page
Allarity Therapeutics
(NASDAQ:ALLR)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.00
▼(-12.28% Downside)
Action:UpgradedDate:03/31/26
The score is driven primarily by weak financial performance (limited revenue, ongoing losses, and historical cash burn) and bearish technical positioning (trading below major moving averages with sub-50 RSI). The recent structured financing adds downside risk via restrictive terms, while valuation is difficult to support given negative earnings.
Positive Factors
Proprietary DRP technology
Allarity’s proprietary drug-response predictor (DRP) anchors a biomarker-driven strategy that can better identify responders in oncology trials. Over months this capability can reduce clinical risk, improve trial hit‑rates, and enhance partnerability and licensing value versus non-targeted approaches.
Negative Factors
Restrictive structured note terms
The March note financing includes tight covenants, security over subsidiary assets, monthly redemption rights and punitive default mechanics. Over the next 18 months these terms materially restrict capital-raising, limit strategic options for subsidiaries, and shift control risk to the lender.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary DRP technology
Allarity’s proprietary drug-response predictor (DRP) anchors a biomarker-driven strategy that can better identify responders in oncology trials. Over months this capability can reduce clinical risk, improve trial hit‑rates, and enhance partnerability and licensing value versus non-targeted approaches.
Read all positive factors
Allarity Therapeutics (ALLR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.82M
Dividend YieldN/A
Average Volume (3M)146.33K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS Growth99.82%
CountryUS
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.19
Shares Outstanding15,818,980
10 Day Avg. Volume114,973
30 Day Avg. Volume146,334
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.58
Price to Sales (P/S)48.53
P/FCF Ratio-1.05
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue17.30
Enterprise Value/Gross Profit17.30
Enterprise Value/Ebitda-0.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Allarity Therapeutics Business Overview & Revenue Model
Company Description
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenopa...
How the Company Makes Money
null...
Allarity Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 320.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 320.00K | 0.00 | -37.00K | -120.00K | -106.00K |
| EBITDA | -11.05M | -24.23M | -11.28M | -17.30M | -25.77M |
| Net Income | -11.23M | -24.52M | -11.90M | -16.06M | -26.65M |
Balance Sheet | |||||
| Total Assets | 18.26M | 22.65M | 11.86M | 14.54M | 49.63M |
| Cash, Cash Equivalents and Short-Term Investments | 14.69M | 19.53M | 166.00K | 2.03M | 19.91M |
| Total Debt | 1.40M | 1.35M | 1.30M | 3.73M | 1.09M |
| Total Liabilities | 8.43M | 10.84M | 14.61M | 12.65M | 30.85M |
| Stockholders Equity | 9.83M | 11.81M | -2.75M | 1.89M | 18.78M |
Cash Flow | |||||
| Free Cash Flow | -14.83M | -17.65M | -12.74M | -16.84M | -15.05M |
| Operating Cash Flow | -14.82M | -17.35M | -12.74M | -16.82M | -15.05M |
| Investing Cash Flow | -8.00K | -298.00K | 0.00 | 791.00K | 1.00M |
| Financing Cash Flow | 10.65M | 36.79M | 10.99M | -1.31M | 33.82M |
Allarity Therapeutics Technical Analysis
Positive
1.14
Price Trends
1.06
Positive
1.09
Positive
1.20
Negative
Market Momentum
0.03
Negative
54.75
Neutral
74.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLR, the sentiment is Positive. The current price of 1.14 is below the 20-day moving average (MA) of 1.15, above the 50-day MA of 1.06, and below the 200-day MA of 1.20, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 54.75 is Neutral, neither overbought nor oversold. The STOCH value of 74.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALLR.
Allarity Therapeutics Risk Analysis
Allarity Therapeutics disclosed 87 risk factors in its most recent earnings report. Allarity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allarity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $45.07M | -0.97 | -84.39% | ― | ― | 15.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $26.06M | -0.39 | -119.92% | ― | -22.41% | 78.88% | |
46 Neutral | $24.78M | -17.14 | 354.21% | ― | 13.56% | 52.92% | |
41 Neutral | $18.82M | -1.15 | -112.05% | ― | ― | 99.82% |
* Healthcare Sector Average
ALLR
Allarity Therapeutics
1.19
0.39
48.75%
LSTA
Lisata Therapeutics
4.53
2.45
117.79%
CRIS
Curis
0.62
-0.67
-51.63%
LGVN
Longeveron
1.12
-0.29
-20.57%
Allarity Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Allarity Therapeutics Secures $20 Million Structured Note Financing
Negative
Mar 6, 2026
On March 2, 2026, Allarity Therapeutics entered into a note purchase agreement with Streeterville Capital under which it issued an unsecured A-1 promissory note with an original principal amount of $10.93 million and a secured B note of $10 millio...
Private Placements and Financing
Allarity Therapeutics Secures Flexible Equity Financing Facility
Neutral
Jan 29, 2026
On January 28, 2026, Allarity Therapeutics, Inc. entered into a Common Stock Purchase Agreement with Tumim Stone Capital LLC, giving the company the right, but not the obligation, to sell up to $6 million of newly issued common shares, or a lower ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.